Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MAdCAM-1

MAdCAM-1

Brief Information

Name:Mucosal addressin cell adhesion molecule-1
Target Synonym:Mucosal addressin cell adhesion molecule 1,MADCAM1,hMAdCAM-1,Mucosal Vascular Addressin Cell Adhesion Molecule 1,MACAM1,MAdCAM-1,Mucosal Addressin Cell Adhesion Molecule-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

MAM-H52H4-SPR
 MAdCAM-1 SPR

Human MAdCAM-1, His Tag (Cat. No. MAM-H52H4) immobilized on CM5 Chip can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) with an affinity constant of 0.227 μM as determined in a SPR assay (Biacore 8K) (QC tested).

MAM-H5253-ELISA
 MAdCAM-1 ELISA

Immobilized Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) at 1 μg/mL (100 μL/well) can bind Human MAdCAM-1, Fc Tag (Cat. No. MAM-H5253) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

MAdCAM-1,Mucosal vascular addressin cell adhesion molecule 1 transcript variant 1

Background

The mucosal addressin cell adhesion molecule-1 (MAdCAM-1) takes a key role in the endothelial adhesion and migration of lymphocytes to sites of inflammation in inflammatory disease. In vitro and in vivo data indicate that blockade of the adhesion molecule mucosal address in cell adhesion molecule (MAdCAM) pathway decreases leukocyte homing to the gut by inhibiting the interaction between MAdCAM and its ligand the α4β7 integrin expressed on lymphocytes.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio United States Colitis, Ulcerative; Crohn Disease Takeda Pharmaceuticals U.S.A. Inc 2014-05-20 Solid tumours; HIV Infections; Hematopoietic stem cell transplantation (HSCT); Acquired Immunodeficiency Syndrome; Inflammatory Bowel Diseases; Pediatric Crohn's disease; Pouchitis; Colitis; Cholangitis, Sclerosing; Celiac Disease; Pediatric ulcerative colitis; Colitis, Ulcerative; Urogenital Neoplasms; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Melanoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ontamalimab SHP-647; PF-00547659; PF-547659 Phase 3 Clinical Pfizer Inc Ileitis; Colitis, Ulcerative; Crohn Disease Details
Vedolizumab biosimilar(Polpharma Biologics) PB-016 Phase 3 Clinical Polpharma Biologics Sa Pouchitis; Colitis, Ulcerative; Crohn Disease Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message